Hodge JC, Mitchell E, Pillalamarri V, Toler TL, Bartel F, Kearney HM, Zou YS, Tan W-H, Hanscom C, Kirmani S, Hanson RR, Skinner SA, Rogers C, Everman DB, Boyd E, Mullegama SV, Keelean-Fuller D, Powell CM, Elsea SH, Morton CC, Gusella JF, DuPont B, Chaubey A, Lin AE, Talkowski ME. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities. Mol Psych. 19(3):368-379, 2014.
Hodge JC, Pearce KE, Wang X, Wiktor AE, Oliveria AM, Greipp, PR. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: Validation and extensive clinical experience with 75 cases. Modern Pathol. 27(1):113-127, 2014.
Hodge JC, Pearce KE, Clayton AC, Taran FA, Stewart EA. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol 210(6):572.e1-e7, 2014.
Hand J, Runke C, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 72(4):617-627, 2015.
Hodge JC, Bedroske PB, Pearce KE, Sukov WR. Molecular cytogenetic analysis of JAZF1, PHF1 and YWHAE in endometrial stromal tumors: Discovery of genetic complexity by FISH. J Mol Diag 18(4):516-526, 2016.
Redin C, Brand H, Collins RL, Kammin T, Mitchell E, Hodge JC, et al. The Genomic Landscape of Balanced Cytogenetic Abnormalities Associated with Congenital Anomalies. Nat Genet 49(1):36-45, 2017.
Kanagal-Shamanna R, Hodge JC, et al. Assessing copy number alterations and copy neutral loss of heterozygosity across the genome as best practice: an evidence based review of clinical utility from the Cancer Genomics Consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics 228-229:197-217, 2018.
Hodge JC, Bosler D, Rubinstein L, Shetty S. Molecular and pathologic characterization of AML with double inv(3)(q21q26.2). Cancer Genetics 230:28-36, 2019.